Therapeutic Transformation for Patients with Diabetes and CKD

Document Type

Presentation

Publication Date

3-20-2021

Publication Title

RPA Annual Meeting

Keywords

washington; spokane

Abstract

SGLT2 inhibitors represent a major advance in the treatment of patients with chronic kidney disease due to their ability to slow progression of CKD and delay the need for dialysis. They also have been shown to have cardio-protective effects.

Clinical Institute

Kidney & Diabetes

Department

Nephrology


Share

COinS